PubRank

Alnawaz Rehemtulla

Author PubWeight™ 130.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005 4.63
2 CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007 3.85
3 Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005 3.15
4 Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 2012 2.95
5 Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 2010 2.90
6 Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008 2.84
7 Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006 2.46
8 Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007 2.39
9 The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 2009 2.32
10 The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006 2.30
11 Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003 2.28
12 A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol 2009 2.10
13 Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A 2002 1.93
14 In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther 2003 1.77
15 Molecular imaging of Akt kinase activity. Nat Med 2007 1.68
16 Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 2006 1.66
17 A methodology for registration of a histological slide and in vivo MRI volume based on optimizing mutual information. Mol Imaging 2006 1.63
18 Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging 2012 1.57
19 Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 2002 1.53
20 A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 2007 1.50
21 Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. J Magn Reson Imaging 2011 1.50
22 Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res 2007 1.48
23 Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A 2005 1.44
24 AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A 2009 1.43
25 Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 2004 1.42
26 Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res 2011 1.39
27 Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res 2006 1.34
28 Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 2007 1.31
29 An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 2007 1.26
30 Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res 2008 1.26
31 A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 2008 1.25
32 The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 2004 1.25
33 A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging 2003 1.25
34 Dynamic imaging of emerging resistance during cancer therapy. Cancer Res 2006 1.23
35 Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res 2008 1.21
36 Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem 2009 1.20
37 Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res 2007 1.16
38 Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging 2009 1.15
39 Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One 2011 1.12
40 Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res 2010 1.10
41 Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol 2008 1.09
42 Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 2011 1.07
43 Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl Oncol 2010 1.06
44 Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther 2012 1.06
45 Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase. J Biol Chem 2005 1.05
46 Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia 2012 1.04
47 Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma. Magn Reson Med 2005 1.01
48 Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer. Cell Cycle 2005 1.01
49 Intravoxel water diffusion heterogeneity imaging of human high-grade gliomas. NMR Biomed 2010 1.00
50 Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors. Magn Reson Imaging 2006 0.99
51 Comparison of apparent diffusion coefficients and distributed diffusion coefficients in high-grade gliomas. J Magn Reson Imaging 2010 0.99
52 Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. Anal Biochem 2007 0.98
53 TRAIL and anti-tumor responses. Cancer Biol Ther 2003 0.98
54 Continuous arterial spin labeling using a train of adiabatic inversion pulses. J Magn Reson Imaging 2005 0.98
55 Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy. Appl Opt 2007 0.98
56 Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed 2006 0.97
57 DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. PLoS One 2012 0.96
58 Molecular imaging of TGFβ-induced Smad2/3 phosphorylation reveals a role for receptor tyrosine kinases in modulating TGFβ signaling. Clin Cancer Res 2011 0.96
59 Targeted imaging and therapy of brain cancer using theranostic nanoparticles. Mol Pharm 2010 0.94
60 Diffusion-weighted MRI for assessment of early cancer treatment response. Curr Pharm Biotechnol 2010 0.94
61 Molecular imaging of protein kinases. Cell Cycle 2007 0.93
62 NanoLuc reporter for dual luciferase imaging in living animals. Mol Imaging 2013 0.93
63 Molecular imaging of glycogen synthase kinase-3beta and casein kinase-1alpha kinases. Anal Biochem 2010 0.92
64 Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res 2010 0.90
65 DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model. NMR Biomed 2011 0.90
66 Imaging proteolytic activity in live cells and animal models. PLoS One 2013 0.89
67 Enhancing Akt imaging through targeted reporter expression. Mol Imaging 2009 0.88
68 Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem 2009 0.88
69 Ultraviolet radiation-induced apoptosis is mediated by Daxx. Neoplasia 2002 0.88
70 Radiosynthesis and evaluation of 5-[125I]iodoindol-3-yl-beta-D-galactopyranoside as a beta-galactosidase imaging radioligand. Mol Imaging 2009 0.87
71 Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res 2006 0.87
72 Novel molecular imaging platform for monitoring oncological kinases. Cancer Cell Int 2010 0.87
73 Molecular imaging of c-Met tyrosine kinase activity. Anal Biochem 2011 0.87
74 Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study. J Neurooncol 2005 0.87
75 Molecular imaging of epidermal growth factor receptor kinase activity. Anal Biochem 2011 0.86
76 Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis. Clin Cancer Res 2008 0.86
77 Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. Cancer Gene Ther 2005 0.86
78 Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin. Neoplasia 2013 0.86
79 Assessment of multiexponential diffusion features as MRI cancer therapy response metrics. Magn Reson Med 2010 0.85
80 High-throughput molecular imaging for the identification of FADD kinase inhibitors. J Biomol Screen 2010 0.85
81 Multimodality imaging of tumor and bone response in a mouse model of bony metastasis. Transl Oncol 2012 0.85
82 Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model. Cancer Res 2003 0.85
83 Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand. PLoS One 2011 0.84
84 High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res 2002 0.84
85 Parametric response mapping of CT images provides early detection of local bone loss in a rat model of osteoporosis. Bone 2012 0.84
86 Synthesis and characterization of silica-embedded iron oxide nanoparticles for magnetic resonance imaging. J Nanosci Nanotechnol 2004 0.83
87 High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer. Transl Oncol 2013 0.83
88 DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases. Transl Oncol 2013 0.83
89 Diffusion-Weighted MRI as a Biomarker of Tumor Radiation Treatment Response Heterogeneity: A Comparative Study of Whole-Volume Histogram Analysis versus Voxel-Based Functional Diffusion Map Analysis. Transl Oncol 2013 0.83
90 Multimodal imaging of growth and rapamycin-induced regression of colonic adenomas in apc mutation-dependent mouse. Transl Oncol 2012 0.83
91 Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization. J Biol Chem 2013 0.82
92 Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma. Clin Cancer Res 2012 0.82
93 Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells. Oncogene 2002 0.81
94 Applications of molecular imaging. Prog Mol Biol Transl Sci 2010 0.81
95 PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development. Curr Comput Aided Drug Des 2008 0.81
96 Identification of peptides that bind to irradiated pancreatic tumor cells. Int J Radiat Oncol Biol Phys 2005 0.81
97 Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer. Clin Cancer Res 2010 0.81
98 Molecular imaging of akt enables early prediction of response to molecular targeted therapy. Transl Oncol 2011 0.80
99 A novel kinase inhibitor of FADD phosphorylation chemosensitizes through the inhibition of NF-κB. Mol Cancer Ther 2011 0.80
100 Molecular imaging of the ATM kinase activity. Int J Radiat Oncol Biol Phys 2013 0.80
101 Imaging of proteolytic activity using a conditional cell surface receptor. Mol Imaging 2006 0.79
102 Noninvasive imaging of apoptosis induced by adenovirus-mediated cancer gene therapy using a caspase-3 biosensor in living subjects. Mol Imaging 2014 0.79
103 Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively. Cancer Res 2014 0.78
104 Evaluation of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on the 9L rat brain tumor model using MRI. NMR Biomed 2003 0.77
105 A transgenic mouse for imaging caspase-dependent apoptosis within the skin. J Invest Dermatol 2010 0.77
106 Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells. Mol Imaging 2015 0.75
107 Advanced MRI: translation from animal to human in brain tumor research. Neuroimaging Clin N Am 2009 0.75
108 Predicting treatment efficacy via quantitative magnetic resonance imaging: a Bayesian joint model. J R Stat Soc Ser C Appl Stat 2011 0.75